At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 83 enrolled
Drug / intervention
AC-150 Combo +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Randomized, Double-Masked Evaluation of the Efficacy of Cetirizine 0.1%/Fluticasone 0.005% Ophthalmic Solution Compared to Its Components and Vehicle in a Modified Conjunctival Allergen Challenge (CAC) Model During Pollen Season
In Brief
A Phase 2 clinical trial evaluating AC-150 Combo, AC-150A 0.1%, and 2 other interventions for Allergic Conjunctivitis. Completed, enrolled 83 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the efficacy of AC-150 compared to vehicle and its components in the prevention of the signs and symptoms of allergic conjunctivitis in Enviro-CAC™ Model.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
First PostedJun 2010
Primary CompletionJul 2010
TodayJul 2026
First PostedJun 2, 2010
Enrollment StartMay 1, 2010
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 16.1 years ago
Interventions
AC-150 Combodrug
1 drop in each eye for up to 14 days
AC-150A 0.1%drug
1 drop in each eye once per day for up to 14 days
AC-150B 0.005%drug
1 drop in each eye once per day for up to 14 days
Vehicledrug
1 drop in each eye once per day for up to 14 days